CSIMarket Company Name, Ticker, Customers, else..
 
Zevra Therapeutics Inc   (NASDAQ: ZVRA)
 
Price: $12.3000 $0.24 1.990%
Day's High: $12.390000343322754 Week Perf: 3.8 %
Day's Low: $ 12.04 30 Day Perf: 16.92 %
Volume (M): 1,176,847 52 Wk High: $ 15.03
Volume (M$): $ 0 52 Wk Avg: $10.11
Open: $12.07 52 Wk Low: $7.16



 Market Capitalization (Millions $) 741
 Shares Outstanding (Millions) 60
 Employees 61
 Revenues (TTM) (Millions $) 115
 Net Income (TTM) (Millions $) 124
 Cash Flow (TTM) (Millions $) 58
 Capital Exp. (TTM) (Millions $) 1

Business Description


Zevra Therapeutics Inc is a pharmaceutical company that focuses on developing innovative and effective treatment options for various medical conditions. They are dedicated to advancing medical science through research and development of novel therapeutics. The company aims to address unmet medical needs and improve the lives of patients by bringing forward safe and reliable therapies. Zevra Therapeutics Inc aims to collaborate with healthcare professionals, patients, and partners to bring their products to market and make a positive impact in the healthcare industry.


   Company Address: 101 Federal Street Boston 2110 MA
   Company Phone Number: 958-1253   Stock Exchange / Ticker: NASDAQ ZVRA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD   -2.2%    
ALKS   -2.93%    
BMRN        2.07% 
HRMY        8.07% 
JAZZ   -1.49%    
SUPN   -1.89%    
• View Complete Report
   



Clinical Study

Pioneering Progress in Rare Diseases Insights from Zevra Therapeutics Presentation of MIPLYFFA at ICIEM

Published Thu, Aug 28 2025 11:45 AM UTC

Zevra Therapeutics, a commercial-stage biopharmaceutical company specialized in rare diseases, has publicly announced the impending presentation of pivotal data on its drug MIPLYFFA (arimoclomol) at the International Congress of Inborn Errors of Metabolism (ICIEM) set for September 2-6, 2025, in Kyoto, Japan. This article aims to outline the key facts surrounding this announ...
Management Announcement

Zevra Therapeutics Gains Strong Support from Proxy Firms Amid Record Growth and Disease Awareness Initiative,

Published Wed, May 21 2025 11:30 AM UTC

In a notable development within the biotechnology and pharmaceutical sector, all three leading proxy advisory firms, Institutional Shareholder Services (ISS), Glass Lewis, and Egan-Jones, have unanimously recommended that Zevra Therapeutics Inc. stockholders vote in favor of the company’s director nominees. This consensus comes in the wake of a rising chorus of challenges ...
Product Service News

Zevra Therapeutics Launches Pioneering Campaign for Niemann-Pick Disease Type C Awareness Amid Financial Challenges

Published Fri, Feb 28 2025 12:59 PM UTC

In the ever-evolving landscape of biotechnology and pharmaceuticals, the proactive approach to disease awareness and early diagnosis has never been more critical. Zevra Therapeutics Inc. a company dedicated to pioneering treatments for rare diseases, is stepping up its commitment with the launch of the Learn NPC, Read Between the Signs campaign. This new initiative aims to e...
Merger and Acquisition

Zevra Therapeutics’ Bold Move: Cashing in $150 Million from Rare Disease Voucher Sale!,

Published Thu, Feb 27 2025 12:31 PM UTC

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million: Strategic Moves in a Dynamic MarketCelebration, Fla. Feb. 27, 2025 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a prominent player in the pharmaceutical industry dedicated to developing therapies for individuals with rare diseases, has made waves in the market ...
Management Announcement

Zevra Therapeutics Announces Organizational Changes

Published Fri, Dec 6 2024 10:00 PM UTC

Article for the CSI MarketZevra Therapeutics: Transformational Challenges Amidst Financial Strain in Rare Disease TherapeuticsCELEBRATION, Fla. — In a striving industry defined by rapid innovation and harsh competition, Zevra Therapeutics, Inc. (NASDAQ: ZVRA) finds itself at a critical juncture. The company, dedicated to addressing the unmet therapeutic needs of patients...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 6.12
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 6.44
Price to Sales (Expected) -
Price to Book 3.6
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.27
Working Capital Ratio 4.89
Leverage Ratio (MRQ) 0.35
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) 2.96

Per Share Current
Earnings (TTM) 2.01 $
Revenues (TTM) 1.91 $
Cash Flow (TTM) 0.97 $
Cash 3.33 $
Book Value 3.42 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,886,443
Net Income per Employee (TTM) 2,036,361
Receivable Turnover Ratio (TTM) 5.72
Inventory Turnover Ratio (TTM) 10.44
Asset Turnover Ratio (TTM) 0.42

Profitability Ratios Current
Gross Margin (MRQ) 93.46 %
Operating Margin (MRQ) 179.79 %
Net Margin (MRQ) 130.64 %
Net Cash Flow Margin (MRQ) 114.43 %
Effective Tax Rate (TTM) 6.88 %

Management Effectiveness Current
Return On Assets (TTM) 45.5 %
Return On Investment (TTM) 52.39 %
Return On Equity (TTM) 81.34 %
Dividend Yield -
Pay out Ratio (TTM) -



Zevra Therapeutics Inc's Segments
Reportable Segment    124.88 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.